A phase 2 study of FG 001 in head and neck cancer (oral squamous cell carcinoma cancer).
Latest Information Update: 06 Feb 2025
At a glance
- Drugs FG 001 (Primary)
- Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Feb 2025 New trial record
- 15 Jan 2025 According to a FluoGuide media release, trial completion is expected in H2 2026.
- 15 Jan 2025 According to a FluoGuide media release, the key data trigger point from this study is expected in the second half of 2025 with the interim data.